Modulation by decitabine of gene expression and growth of osteosarcoma U2OS cells in vitro and in xenografts: Identification of apoptotic genes as targets for demethylation |
| |
| Authors: | Khaldoun Al-Romaih Gino R Somers Jane Bayani Simon Hughes Mona Prasad Jean-Claude Cutz Hui Xue Maria Zielenska Yuzhuo Wang Jeremy A Squire |
| |
| Affiliation: | (1) Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada, M5G 1L5;(2) The Ontario Cancer Institute, Princess Margaret Hospital, Toronto, Canada, M5G 2M9;(3) Department of Pediatric Laboratory Medicine, Hospital for Sick Children, Toronto, Canada, M5G 1X8;(4) Department of Cancer Endocrinology, British Columbia Cancer Agency, Vancouver, Canada, V5Z 1L3;(5) Departments of Pathology & Molecular Medicine, and Laboratory Medicine, McMaster University, St. Joseph's Healthcare – Hamilton Regional Laboratory Medicine Program, Hamilton, Canada, L8N 4A6;(6) Division of Tumor Biology, Institute of Cancer and Cancer Research, UK Clinical Centre, Barts and the London School of Medicine and Dentistry, John Vane Science Centre, Charterhouse Square, London, United Kingdom, EC1M 6BQ;(7) The Prostate Centre, Vancouver General Hospital, Vancouver, Canada, V6H 3Z6 |
| |
| Abstract: | Background Methylation-mediated silencing of genes is one epigenetic mechanism implicated in cancer. Studies regarding the role of modulation of gene expression utilizing inhibitors of DNA methylation, such as decitabine, in osteosarcoma (OS) have been limited. A biological understanding of the overall effects of decitabine in OS is important because this particular agent is currently undergoing clinical trials. The objective of this study was to measure the response of the OS cell line, U2OS, to decitabine treatment both in vitro and in vivo. |
| |
| Keywords: | |
| 本文献已被 SpringerLink 等数据库收录！ |
|
